 Lexicon Pharmaceuticals NASDAQ:LXRXs stock had its buy rating reaffirmed by equities research analysts at Wedbush in a report released on Monday, TipRanks reports. They presently have a 3.00 price target on the biopharmaceutical companys stock. Wedbushs target price would indicate a potential upside of 57.89 from the companys previous close. Other equities research analysts also ... 